menu
    • menu

    Company profile for Aspen Pharmacare Holdings

    Aspen API-PSE
    News
    Aspen shells out $100M for Sandoz's China unit, pipeline

    04 Dec 2023

    // Zoey Becker FIERCE PHARMA

    Novo Nordisk taps Aspen to help produce insulin for Africa

    19 Sep 2023

    // Fraiser Kansteiner FIERCE PHARMA

    Aspen and Lilly enter into agreement in South Africa and the rest of Sub-Saharan Africa

    30 Aug 2023

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Aspen API

    Contact Supplier

    Website

    PackExpo

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    speak-pharma/due-to-its-20-year-mastery-in-micronization-inke-has-emerged-a-cornerstone-in-treating-global-respiratory-diseases

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    South African-based Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the world and of consumer and nutritional products in selected territories. Aspen is represented in South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, France, Germany, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States of America. Acquisitions announced in 2013 will further extend the Group’s emerging market presence to the Commonwealth of Independent States, comprising Russia and the former Soviet Republics.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aspen Pharmacare HoldingsSouthAfrica Flag
    Country
    Country
    South Africa
    Address
    Address
    Aspen House, Aspen Park 98 Armstrong Avenue La Lucia Ridge, Durban
    Telephone
    Telephone
    +27 31 580-8600
    Client Email
    Email
    api@nl.aspenpharma.com
    Client Website
    Website
    https://www.aspenpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aspen-pharmacare-global/
    youtube
    YouTube
    Twitter
    Twitter
    https://twitter.com/aspenpharma
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI India 2024

    CPhI India 2024

    Not Confirmed

    envelop Contact Supplier

    CPhI India 2024

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Aspen shells out $100M for Sandoz's China unit, pipeline
    Aspen shells out $100M for Sandoz's China unit, pipeline

    04 Dec 2023

    // Zoey Becker FIERCE PHARMA

    https://www.fiercepharma.com/pharma/south-africas-aspen-expands-reach-china-100m-buy-sandoz-chinese-business

    Zoey Becker FIERCE PHARMA
    04 Dec 2023
    Share Share
    Novo Nordisk taps Aspen to help produce insulin for Africa
    Novo Nordisk taps Aspen to help produce insulin for Africa

    19 Sep 2023

    // Fraiser Kansteiner FIERCE PHARMA

    https://www.fiercepharma.com/pharma/following-eli-lilly-novo-nordisk-links-aspen-produce-insulin-africa

    Fraiser Kansteiner FIERCE PHARMA
    19 Sep 2023
    Share Share
    Aspen and Lilly enter into agreement in South Africa and the rest of Sub-Saharan Africa
    Aspen and Lilly enter into agreement in South Africa and the rest of Sub-Saharan Africa

    30 Aug 2023

    // PRESS RELEASE

    https://www.aspenpharma.com/aspen-and-lilly-enter-into-agreement-in-south-africa-and-the-rest-of-sub-saharan-africa/

    PRESS RELEASE
    30 Aug 2023
    Share Share
    Aspen revenue exceeds R40 billion with accelerated medium-term growth anticipated
    Aspen revenue exceeds R40 billion with accelerated medium-term growth anticipated

    30 Aug 2023

    // PRESS RELEASE

    https://www.aspenpharma.com/aspen-revenue-exceeds-r40-billion-with-accelerated-medium-term-growth-anticipated/

    PRESS RELEASE
    30 Aug 2023
    Share Share
    Aspen hosts Mandela Day for 13th consecutive year, having reached 865 000 beneficiaries
    Aspen hosts Mandela Day for 13th consecutive year, having reached 865 000 beneficiaries

    18 Jul 2023

    // PRESS RELEASE

    https://www.aspenpharma.com/aspen-hosts-mandela-day-for-13th-consecutive-year-having-reached-865-000-beneficiaries/

    PRESS RELEASE
    18 Jul 2023
    Share Share
    Aspen, Saudi Chemical Company Holding and its subsidiary AJA Pharma enter into a memorandum of understanding.
    Aspen, Saudi Chemical Company Holding and its subsidiary AJA Pharma enter into a memorandum of understanding.

    18 Jul 2023

    // PRESS RELEASE

    https://www.aspenpharma.com/aspen-hosts-mandela-day-for-13th-consecutive-year-having-reached-865-000-beneficiaries/

    PRESS RELEASE
    18 Jul 2023
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aspen Concludes Two Significant Agreements with Sandoz for China and Europe

    Details:

    The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.


    Lead Product(s): Octreotide Acetate

    Therapeutic Area: Endocrinology Brand Name: Sandostatin LAR Depot

    Study Phase: ApprovedProduct Type: Peptide

    Recipient: Sandoz B2B

    Deal Size: $99.9 million Upfront Cash: Undisclosed

    Deal Type: Agreement December 04, 2023

    Aspen API Comapny Banner

    01

    Aspen Pharmacare Holdings

    South Africa
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Octreotide Acetate

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved

    Recipient : Sandoz B2B

    Deal Size : $99.9 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Aspen Concludes Two Significant Agreements with Sandoz for China and Europe

    Details : The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.

    Brand Name : Sandostatin LAR Depot

    Molecule Type : Peptide

    Upfront Cash : Undisclosed

    December 04, 2023

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aspen, CEPI And The Bill & Melinda Gates Foundation Expand Commitments To Improve Access To Vaccines In Africa

    Details:

    PNEUMOSIL® (pneumococcal polysaccharide conjugate vaccine – adsorbed, 10 Valent), a well-designed vaccine, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.


    Lead Product(s): Pneumococcal Polysaccharide Conjugate Vaccine

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Pneumosil

    Study Phase: ApprovedProduct Type: Vaccine

    Sponsor: Gates Foundation

    Deal Size: $30.0 million Upfront Cash: Undisclosed

    Deal Type: Funding December 12, 2022

    Aspen API Comapny Banner

    02

    Aspen Pharmacare Holdings

    South Africa
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pneumococcal Polysaccharide Conjugate Vaccine

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Gates Foundation

    Deal Size : $30.0 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Aspen, CEPI And The Bill & Melinda Gates Foundation Expand Commitments To Improve Access To Vaccin...

    Details : PNEUMOSIL® (pneumococcal polysaccharide conjugate vaccine – adsorbed, 10 Valent), a well-designed vaccine, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.

    Brand Name : Pneumosil

    Molecule Type : Vaccine

    Upfront Cash : Undisclosed

    December 12, 2022

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aspen Concludes a Collaboration Agreement to Manufacture and Make Available Four Aspen-Branded Vaccines for Africa

    Details:

    PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.


    Lead Product(s): 10 Valent Pneumococcal Polysaccharide Conjugate Vaccine

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Pneumosil

    Study Phase: ApprovedProduct Type: Vaccine

    Sponsor: Serum Institute of India

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration August 31, 2022

    Aspen API Comapny Banner

    03

    Aspen Pharmacare Holdings

    South Africa
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 10 Valent Pneumococcal Polysaccharide Conjugate Vaccine

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Serum Institute of India

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Aspen Concludes a Collaboration Agreement to Manufacture and Make Available Four Aspen-Branded Vac...

    Details : PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countrie...

    Brand Name : Pneumosil

    Molecule Type : Vaccine

    Upfront Cash : Undisclosed

    August 31, 2022

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Australia Registers First Eye Drops to Slow Short-sightedness Progress in Children

    Details:

    EIKANCE (atropine sulfate monohydrate eye drops) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and may be initiated in children when myopia progresses by 1 or more diopters per year.


    Lead Product(s): Atropine Sulfate

    Therapeutic Area: Ophthalmology Brand Name: Eikance

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 18, 2022

    Aspen API Comapny Banner

    04

    Aspen Pharmacare Holdings

    South Africa
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Australia Registers First Eye Drops to Slow Short-sightedness Progress in Children

    Details : EIKANCE (atropine sulfate monohydrate eye drops) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and may be initiated in children when myopia progresses by 1 or more diopters per year.

    Brand Name : Eikance

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    March 18, 2022

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Debiopharm And Aspen Partner To Launch Prostate Cancer Drug Trelstar® In South Africa

    Details:

    Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer patients in this region.


    Lead Product(s): Triptorelin Pamoate

    Therapeutic Area: Oncology Brand Name: Trelstar

    Study Phase: ApprovedProduct Type: Peptide

    Sponsor: Debiopharm

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership February 01, 2022

    Aspen API Comapny Banner

    05

    Aspen Pharmacare Holdings

    South Africa
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Triptorelin Pamoate

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Debiopharm

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Debiopharm And Aspen Partner To Launch Prostate Cancer Drug Trelstar® In South Africa

    Details : Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer pat...

    Brand Name : Trelstar

    Molecule Type : Peptide

    Upfront Cash : Undisclosed

    February 01, 2022

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage

    Details:

    The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.


    Lead Product(s): Ad26.COV2.S

    Therapeutic Area: Infections and Infectious Diseases Brand Name: JNJ-78436735

    Study Phase: ApprovedProduct Type: Vaccine

    Sponsor: Johnson & Johnson

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement November 30, 2021

    Aspen API Comapny Banner

    06

    Aspen Pharmacare Holdings

    South Africa
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ad26.COV2.S

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Johnson & Johnson

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage

    Details : The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.

    Brand Name : JNJ-78436735

    Molecule Type : Vaccine

    Upfront Cash : Undisclosed

    November 30, 2021

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acino Acquires Selected Aspen Brands in South Africa

    Details:

    The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.


    Lead Product(s): Esomeprazole Magnesium

    Therapeutic Area: Gastroenterology Brand Name: Trustan

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Acino Pharma

    Deal Size: $119.4 million Upfront Cash: Undisclosed

    Deal Type: Acquisition October 22, 2021

    Aspen API Comapny Banner

    07

    Aspen Pharmacare Holdings

    South Africa
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esomeprazole Magnesium

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Acino Pharma

    Deal Size : $119.4 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Acino Acquires Selected Aspen Brands in South Africa

    Details : The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.

    Brand Name : Trustan

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 22, 2021

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals

    Details:

    Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy due to menopause.


    Lead Product(s): Conjugated Estrogens

    Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Cenestin

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Avion Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership November 12, 2020

    Aspen API Comapny Banner

    08

    Aspen Pharmacare Holdings

    South Africa
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Conjugated Estrogens

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Avion Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals

    Details : Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy d...

    Brand Name : Cenestin

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    November 12, 2020

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Divestment of Aspen’s European Thrombosis Business to Mylan and Withdrawal of Cautionary

    Details:

    Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.


    Lead Product(s): Fondaparinux Sodium

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Arixtra

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Viatris

    Deal Size: $757.2 million Upfront Cash: $310.4 million

    Deal Type: Acquisition September 08, 2020

    Aspen API Comapny Banner

    09

    Aspen Pharmacare Holdings

    South Africa
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fondaparinux Sodium

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Viatris

    Deal Size : $757.2 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Divestment of Aspen’s European Thrombosis Business to Mylan and Withdrawal of Cautionary

    Details : Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.

    Brand Name : Arixtra

    Molecule Type : Small molecule

    Upfront Cash : $310.4 million

    September 08, 2020

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent ...

    Details:

    The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan like Lidocaine Hydrochloride.


    Lead Product(s): Lidocaine Hydrochloride

    Therapeutic Area: Neurology Brand Name: Lidocaine HCl-Generic

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Sandoz B2B

    Deal Size: $440.0 million Upfront Cash: $330.0 million

    Deal Type: Acquisition January 31, 2020

    Aspen API Comapny Banner

    10

    Aspen Pharmacare Holdings

    South Africa
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lidocaine Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Sandoz B2B

    Deal Size : $440.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world...

    Details : The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan like Lidocaine Hydrochloride.

    Brand Name : Lidocaine HCl-Generic

    Molecule Type : Small molecule

    Upfront Cash : $330.0 million

    January 31, 2020

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search